Potential Clinical and Immunotherapeutic Utility of Talimogene Laherparepvec for Patients With Melanoma After Disease Progression on Immune Checkpoint Inhibitors and BRAF Inhibitors

Melanoma Research - United States
doi 10.1097/cmr.0000000000000444
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Combining Checkpoint Inhibitors and BRAF-targeted Agents Against Metastatic Melanoma

OncoImmunology
OncologyAllergyImmunology
2013English

Immune Checkpoint Inhibitors in Melanoma: Review and Update

Journal of the Portuguese Society of Dermatology and Venereology
2018English

Impact of Clinicopathological Characteristics on Survival in Patients Treated With Immune Checkpoint Inhibitors for Metastatic Melanoma

International Journal of Cancer
Cancer ResearchOncology
2018English

Biodistribution, Shedding, and Transmissibility of the Oncolytic Virus Talimogene Laherparepvec in Patients With Melanoma

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Immune Checkpoint Inhibitors and irAEs

Trends in Immunotherapy
2018English

Patterns of Failure After Immunotherapy With Checkpoint Inhibitors Predict Durable Progression-Free Survival After Local Therapy for Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Cardiotoxicity of Immune Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Immune Checkpoint Inhibitors Therapy in Older Patients (≥ 70 Years) With Metastatic Melanoma: A Multicentre Study

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy